**Psilocybin Advisory Board Research Subcommittee**

**Meeting Minutes**

June 24, 2021

Research Subcommittee Members in Attendance:

1) Atheir Abbas X

2) Angela Carter X

3) Tom Jeanne X

4) Rachel Knox X

5) Todd Korthuis X

6) Ali Hamada X

7) Christopher Stauffer X

8) Jessie Uehling X

**1. Review of Minutes**: Subcommittee members reviewed and approved minutes from last meeting.

**2. Draft Evidence Review Update:**

* Review of draft document including summary, recommendations, and appendices
* One RSC member expressed concern that their writing had been removed to an appendix
* Draft appendix and draft report were reviewed so everyone could see where information was moved in the editing process
* Some PAB members expressed discontent with the editing and writing process; Measure 109-directed writing task reviewed, demonstrating that review product aligns with Measure 109 intent. Co-chair reassured that everyone’s input is valued, and that the document honors everyone’s input. Editing process reviewed.
* We reconfirmed consensus on term “potential benefits and risks” instead of “benefits and harms.”
* There was debate on the term “adverse events” or “adverse effects” with some advocating for more favorable terminology. Others pointed out that this is standard language in clinical trials and systematic reviews. No consensus was achieved. The co-chairs will attempt to revise the draft slightly to reflect this.
* Will circulate revised draft for RSC comment
* Any additional edits must be submitted by Sunday June 27, 2021 in order to be incorporated into June 30th report.
* Recommendations slightly edited during meeting.
* Motion to approve Recommendations was approved.
* Co-chairs to finalize edits.

**3. Discussion of Expert Peer Review Process:**

* Ran out of time to review nominations
* PAB encouraged to submit nominations to OHA with CV and conflict of interest statements.
* Will add to agenda for 7/1/2021